Axsome Therapeutics Inc.

5 hours ago · zacks.com

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.

8 hours ago · globenewswire.com

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO ® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update. “Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate.

7 days ago · zacks.com

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 days ago · fool.com

Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.

12 days ago · zacks.com

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

21 days ago · fool.com

Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.

26 days ago · globenewswire.com

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

1 month ago · globenewswire.com

The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one's quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer's disease and their family care partners.

1 month ago · marketbeat.com

Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.

1 month ago · marketbeat.com

Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.